# Applicant

Focus Diagnostics, Inc. 11331 Valley View Street Cypress, California 90630 USA

Establishment Registration No. Contact Person

2023365

Tara Viviani tel 714.822.2115 fax 714.822.3898 tviviani@focusdx.com

May 18, 2010

Simplexa™M Influenza A H1N1 (2009)

Summary Date Proprietary Name Generic Name Classification Predicate Devices

Influenza A H1N1 2009 Real Time RT-PCR

Class II, Special Controls   
Luminex Diagnostics XTAG RESPIRATORY VIRAL PANEL   
(K091667, K081483, K063765)   
CDC Human Influenza Virus Real-Time RT- PCR Detection and   
Characterization Panel (K080570)

# Intended Use

The Focus Diagnostic Simplexa™ InfluenzaH(200)assay sntended or usen the3M Integratece li 20H1N1influenza viral RNA in nasopharyngeal swabs (NPS), nasal swabs (NS), and nasopharyngeal asprates (NPA) fromhuman patients with signs and symptoms of respiratoy infection in conjunction with clinical and epidemiological risk factors.

Nu other patient management decisions.

Perforance characteristics orinfenzaA wereestablishe during the 209-2010influenza seaon when 2009 zaas ezvulatnWhehezvi performance characteristics may vary.

recommended by public health authorities, specimens should be collected with appropriate infection control should not be attempted in these cases unless a BSL $^ { 3 + }$ facility is available to receive and culture specimens.

# Device Description

Simplexa™ Influenza A 11(200) test kit s a nucle acid mpliiation test that uses eal-time ev transcriptase polymerase chain reaction (RT-PCR) amplification to enable simultaneous and distinct detection of influenza A and 2009 H1N1 influenza in a single reaction from nasopharyngeal swabs (NPS), nasal swabs (NS), and nasopharyngeal aspirates (NPA).The assay combines real-time PCR amplification with fluorescent signal detection technology.A bi-functional fluorescent probe-primer is used together with a rever primer o mpliy a speciic target or each analyte and internalconrol. fluoeent sl generated afer the separation  the fluorophore from the quencher as a result of the binding of a probe element to the extended RNA fragment synthesized during amplification.

The 3M Integrated Cycler is a rapid real-time Polymerase Chain Reaction thermocycler used for the identification of nucleic acid from prepared biological samples. The instrument utilizes disk media to contain and to process samples.The instrument uses real time flourometric detection to identify trgets within the sample wells. The instrument is controlled by an external computer running the Integrated Cycer StudSoftaTogeher, te nstent sotar nd test  e eerrd o s he Mi Molecular System."

# K100148

# 510(k) Summary of Safety and Effectiveness Simplexa ™M Influenza A H1N1 (2009) Catalog No. MOL2500 Prepared Date: May 18, 2010 Page 2 of 9

Predicate Device Information   

<table><tr><td rowspan=1 colspan=1>Trade Name / Method</td><td rowspan=1 colspan=1>.510(ksubmitter</td><td rowspan=1 colspan=1>510(k)number</td><td rowspan=1 colspan=1>Decision Date</td><td rowspan=1 colspan=1>Panel</td><td rowspan=1 colspan=1>ProductCode(s)</td></tr><tr><td rowspan=1 colspan=1>XTAG RespiratoryViral Panel - FluA</td><td rowspan=1 colspan=1>Luminex</td><td rowspan=1 colspan=1>K091667K081483K063765</td><td rowspan=1 colspan=1>06/25/200906/25/200811/30/2007</td><td rowspan=1 colspan=1>Microbiology(83)</td><td rowspan=1 colspan=1>OCC, OEM,OEP</td></tr><tr><td rowspan=1 colspan=1>CDC Human InfluenzaVirus Real-Time RT-PCR Detection andCharacterization Panel</td><td rowspan=1 colspan=1>Centers forDiseaseControl andPrevention</td><td rowspan=1 colspan=1>K080570</td><td rowspan=1 colspan=1>09/30/2008</td><td rowspan=1 colspan=1>Microbiology(83)</td><td rowspan=1 colspan=1>NXD, OEP,OCC, NSU</td></tr></table>

<table><tr><td colspan="1" rowspan="1">ItemName</td><td colspan="1" rowspan="1">DeviceSimplexa™ Influenza AH1N1 (2009)</td><td colspan="2" rowspan="1">PredicatexTAG Respiratory Viral       CDC Human InfluenzaPanel - FLUA           Virus Real-Time RT- PCRDetection andCharacterization Panel</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">The Focus DiagnosticsSimplexa ™ Influenza A H1N1(2009) assay is intended foruse on the 3M IntegratedCycler as part of theMicrofluidic Molecular Systemfor the in vitro qualitativedetection and differentiation ofinfluenza A and 2009 H1N1influenza viral RNA innasopharyngeal swabs (NPS),nasal swabs (NS), andnasopharyngeal aspirates(NPA) from human patientswith signs and symptoms ofrespiratory infection inconjunction with clinical andepidemiological risk factors.Negative results do notpreclude influenza virusinfection and should not beused as the sole basis fortreatment or other patientmanagement decisions.Performance characteristicsfor influenza A wereestablished during the 2009-2010 influenza season when2009 H1N1 influenza was thepredominant influenza Aviruses in circulation. Whenother Influenza A viruses areemerging, performancecharacteristics may vary.If infection with a novelInfluenza A virus is suspected</td><td colspan="1" rowspan="1">The xTAG® RespiratoryViral Panel (RVP) is aqualitative nucleic acidmultiplex test intended forthe simultaneous detectionand identification ofmultiple respiratory virusnucleic acids innasopharyngeal swabsfrom individuals suspectedof respiratory tractinfections. The followingvirus types and subtypesare identified using RVP:Influenza A, Influenza Asubtype H1, Influenza Asubtype H3, Influenza B,Respiratory Syncytial Virussubtype A, RespiratorySyncytial Virus subtype B,Parainfluenza 1,Parainfluenza 2, andParainfluenza 3 virus,Human Metapneumovirus,Rhinovirus, andAdenovirus. The detectionand identification of specificviral nucleic acids fromindividuals exhibiting signsand symptoms ofrespiratory infection aids inthe diagnosis of respiratoryviral infection if used inconjunction with other</td><td colspan="1" rowspan="1">The Human Influenza VirusReal-time RT-PCRDetection andCharacterization Panel(rRT-PCR Flu Panel) isintended for use in Real-time RT-PCR assays on anABI 7500 Fast Dx Real-time PCR instrument inconjunction with clinicaland epidemiologicalinformation:* for qualitative detectionof influenza virus type A orB in symptomatic patientsfrom viral RNA innasopharyngeal and/ornasal swab specimens, *for determination of thesubtype of seasonal humaninfluenza A virus, asseasonal A/HI or A/H3, ifpresent, from viral RNA innasopharyngeal and/ornasal swab specimens,* for presumptiveidentification of virus inpatients who may beinfected with influenza Asubtype A/H5 (Asianlineage) from viral RNA inhuman respiratoryspecimens and viral culturein conjunction with clinical</td></tr><tr><td>Item Name</td><td>Device Simplexa™ Influenza A H1N1 (2009) based on current clinical and</td><td>Predicate xTAG Respiratory Viral Panel - FLUA</td><td>CDC Human Influenza Virus Real-Time RT- PCR Detection and</td></tr><tr><td></td><td>epidemiological screening criteria recommended by public health authorities, specimens should be collected with appropriate infection control precautions for novel virulent Influenza viruses and sent to state or local health department for testing. Viral culture should not be attempted in these cases unless a BSL 3+ facility is available to receive and culture specimens.</td><td>clinical and laboratory findings. It is recommended that specimens found to be negative for Influenza B, Respiratory Syncytial Virus subtype A and B, Parainfluenza 1, Parainfluenza 2, Parainfluenza 3 and Adenovirus, after examination using RVP be confirmed by cell culture. Negative results do not preclude respiratory virus infection and should not be used as the sole basis for diagnosis, treatment or other management decisions. Positive results do not rule out bacterial infection, or co-infection with other viruses. The agent detected may not be the definite cause of disease. The use of additional laboratory testing (e.g. bacterial culture, immunofluorescence, radiography) and clinical presentation must be taken into consideration in order to obtain the final diagnosis of respiratory viral infection. Due to seasonal prevalence, performance characteristics for Influenza A/H1 were established primarily with retrospective specimens. The RVP assay cannot</td><td>Characterization Panel and epidemiological risk factors. * to provide epidemiologic information for surveillance for influenza viruses. Performance characteristics for influenza A were established when influenza A/H3 and A/HI were the predominant influenza A viruses in circulation. When other influenza A viruses are emerging, performance characteristics may vary. Testing with the influenza H5a and H5b primer and probe sets should not be performed unless the patient meets the most current U.S. Department of Health and Human Services (DHHS) clinical and epidemiologic criteria for testing suspect A/H5 specimens. The definitive identification of influenza A/H5 (Asian lineage) either directly from patient specimens or from virus cultures requires additional laboratory testing, along with clinical and epidemiological assessment in consultation with national influenza surveillance experts. Negative results do not preclude influenza virus infection and should not be used as the sole basis for</td></tr></table>

<table><tr><td></td><td></td><td></td><td></td><td rowspan=1 colspan=1>−</td></tr><tr><td rowspan=1 colspan=1>ItemName</td><td rowspan=1 colspan=1>DeviceSimplexa™ Influenza AH1N1 (2009)</td><td rowspan=1 colspan=2>PredicatexTAG Respiratory Viral       CDC Human InfluenzaPanel - FLUA           Virus Real-Time RT- PCRDetection andCharacterization Panel</td><td></td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>should be confirmed by analternate method (e.g. cellculture). Performancecharacteristics for InfluenzaA Virus were establishedwhen Influenza A/H3 andA/H1 were the predominantInfluenza A viruses incirculation. When otherInfluenza A viruses areemerging, performancecharacteristics may vary. Ifinfections with a 2009H1N1 Influenza A virus issuspected based oncurrent clinical andepidemiological screeningcriteria recommended bypublic health authorities,specimens should becollected with appropriateinfection controlprecautions for 2009 H1N1virulent Influenza virusesand sent to a state or localhealth department fortesting. Viral culture shouldnot be attempted in thesecases unless a BSL 3+facility is available toreceive and culturespecimens.</td><td rowspan=1 colspan=1>perform and interpret theresults from this procedureby a CDC instructor ordesignee prior to use. CDCInfluenza Division will limitthe distribution of thisdevice to only those userswho have successfullycompleted training providedby CDC instructors ordesignees.</td><td></td></tr><tr><td rowspan=1 colspan=1>Assay Targets</td><td rowspan=1 colspan=1>Influenza A2009 H1N1 Influenza</td><td rowspan=1 colspan=1>Influenza A, Influenza Asubtype H1, Influenza Asubtype H3, Influenza B,Respiratory Syncytial Virussubtype A, RespiratorySyncytial Virus subtype B,Parainfluenza 1,Parainfluenza 2, andParainfluenza 3 virus,Human Metapneumovirus,Rhinovirus, andAdenovirus.</td><td rowspan=1 colspan=1>InIfluenza A/H1Influenza A/H3Influenza A/H5 (asianlineage)Influenza B</td><td></td></tr><tr><td rowspan=1 colspan=1>Sample Types</td><td rowspan=1 colspan=1>NPS, NS, NPA</td><td rowspan=1 colspan=1>NPS</td><td rowspan=1 colspan=1>NPS, NS, viral culture</td><td></td></tr></table>

# K100148

510(k) Summary of Safety and Effectiveness Simplexa ™M Influenza A H1N1 (2009) Catalog No. MOL2500 Prepared Date: May 18, 2010 Page 5 of 9

<table><tr><td rowspan=1 colspan=1>ItemName</td><td rowspan=1 colspan=1>DeviceSimplexa™ Influenza AH1N1 (2009)</td><td rowspan=1 colspan=2>PredicatexTAG Respiratory Viral       CDC Human InfluenzaPanel - FLUA          Virus Real-Time RT- PCRDetection andCharacterization Panel</td></tr><tr><td rowspan=1 colspan=1>ExtractionMethods</td><td rowspan=1 colspan=1>Roche MagNA Pure LCTotal Nucleic Acid IsolationKit,QIAGEN QIAamp ViralRNA Mini Kit</td><td rowspan=1 colspan=1>QIAGEN QIAamp MiniEluteBiomérieux EasyMag,Biomérieux MiniMag</td><td rowspan=1 colspan=1>QIAamp® Viral RNA MiniKit.Qiagen RNeasy® Mini Kit,MagNA Pure LC RNAIsolation Kit IIRoche MagNA Pure LCTotal Nucleic Acid IsolationKit,</td></tr><tr><td rowspan=1 colspan=1>AssayMethodology</td><td rowspan=1 colspan=1>PCR-based system fordetecting the presence /absence of viral RNA inclinical specimens</td><td rowspan=1 colspan=1>PCR-based system fordetecting the presence /absence of viral DNA/RNAin clinical specimens</td><td rowspan=1 colspan=1>PCR-based system fordetecting the presence /absence of viral RNA inclinical specimens</td></tr><tr><td rowspan=1 colspan=1>DetectionTechniques</td><td rowspan=1 colspan=1>Multiplex assay usingdifferent reporter dyes foreach target.</td><td rowspan=1 colspan=1>Multiplex assay using acombination of color codedbeads and differentreporter dyes.</td><td rowspan=1 colspan=1>A panel of oligonucleotideprimers and dual-labeledhydrolysis (TaqMan®)probes for the qualitativedetection and differentiationof influenza virus type andsubtype target sequences.</td></tr><tr><td rowspan=1 colspan=1>Influenza AViral Target</td><td rowspan=1 colspan=1>Well conserved region ofthe matrix gene</td><td rowspan=1 colspan=1>Well conserved region ofthe matrix gene</td><td rowspan=1 colspan=1>Well conserved region ofthe matrix gene</td></tr><tr><td rowspan=1 colspan=1>H1N1 (2009)Viral Target</td><td rowspan=1 colspan=1>Well conserved region ofthe hemagglutinin genespecific for H1N1 (2009)</td><td rowspan=1 colspan=1>n/a</td><td rowspan=1 colspan=1>n/a</td></tr><tr><td rowspan=1 colspan=1>LoD</td><td rowspan=1 colspan=1>Influenza A StrainsTCID5o/mL in a range of1x10-1 to 2.7x102009 H1N1TCID/mL in a range of1x10- to 2.7x101Please refer to detailed tablebelow.</td><td rowspan=1 colspan=1>Influenza AA/PR/8/34 (TCID5/mL =8x10-)AVictoria/3/75 (TCIDs/mL=1x10²</td><td rowspan=1 colspan=1>Influenza AA/New Caledonia/20/1999(TCID5o/mL = 1012)A/Hawaii/15/2001(TCID5o/mL = 101.5)A/New York/55/2004(TCID50/mL = 102)AWisconsin/67/2005(TCIDso/mL = 1012</td></tr><tr><td rowspan=1 colspan=1>Reproducibility</td><td rowspan=1 colspan=1>FLUA Inter-AssayTotal %CV range 0.0 to 4.8FLUA Intra-AssayTotal %CV range 0.0 to 6.6H1N1 Inter-AssayTotal %CV range 0.0 to 1.8H1N1 Intra-AssayTotal %CV range 0.0 to 4.7</td><td rowspan=1 colspan=1>Influenza A - low positive%CV range 29.41 to 60.22Influenza A - medium titer%CV range 5.6 to 35.6</td><td rowspan=1 colspan=1>Influenza A - 1:10 of lowpositive %CV range 1.94 to7.09Influenza A - low positive%CV range 2.12 to 7.89</td></tr></table>

# Reproducibility:

o woee yto day.Two sites performed the extraction using the MagNA Pure LCTotal Nucleic Acid Isolation Kit; one site peformed the extracion step using the Qiagen QlAamp Viral RNA Mini KitCombined results orl si summarized below.

FLUA Inter-Assay Total $\% c v$ range (0.0 to 4.8) FLUA Intra-Assay Total $\% c v$ range (0.0 to 6.6) H1N1 Inter-Assay Total $\% 0 v$ range (0.0 to 1.8) H1N1 Intra-Assay Total $\% C V$ range (0.0 to 4.7)

# Limit of Detection

Simplexa ™M Influenza A H1N1 (2009) Limit of Detection - FLUA   

<table><tr><td rowspan=2 colspan=1>Influenza A Strain</td><td rowspan=1 colspan=2>LoD MagNA Pure extraction(TCIDso/mL)</td><td rowspan=1 colspan=2>LoD QlAgen extraction(TCIDso/mL)</td></tr><tr><td rowspan=1 colspan=1>Swab</td><td rowspan=1 colspan=1>Aspirate</td><td rowspan=1 colspan=1>Swab</td><td rowspan=1 colspan=1>Aspirate</td></tr><tr><td rowspan=1 colspan=1>AVCalifornia/7/2009 NYMC x-179-A</td><td rowspan=1 colspan=1>1.3x10&#x27;</td><td rowspan=1 colspan=1>1.3x10&#x27;</td><td rowspan=1 colspan=1>1.3x10&#x27;</td><td rowspan=1 colspan=1>2.7x10^{</td></tr><tr><td rowspan=1 colspan=1>A/Swine NY/02/2009 H1N1</td><td rowspan=1 colspan=1>1x10-1</td><td rowspan=1 colspan=1>1x10^1</td><td rowspan=1 colspan=1>1x10-1</td><td rowspan=1 colspan=1>1x10^1</td></tr><tr><td rowspan=1 colspan=1>A/Solomon Island/03/06 H1</td><td rowspan=1 colspan=1>5x10r}$</td><td rowspan=1 colspan=1>5x10}$</td><td rowspan=1 colspan=1>1x10}$</td><td rowspan=1 colspan=1>1x10}$</td></tr><tr><td rowspan=1 colspan=1>A/Brisbane/59/07 H1</td><td rowspan=1 colspan=1>1x100}$</td><td rowspan=1 colspan=1>$1x10o}$</td><td rowspan=1 colspan=1>$1x10}$</td><td rowspan=1 colspan=1>1x10}$</td></tr><tr><td rowspan=1 colspan=1>A/Brisbane/10/07 H3</td><td rowspan=1 colspan=1>1x10^1</td><td rowspan=1 colspan=1>1x10^1</td><td rowspan=1 colspan=1>5x10^</td><td rowspan=1 colspan=1>5x10-1</td></tr><tr><td rowspan=1 colspan=1>AWisconsin/67/05 H3</td><td rowspan=1 colspan=1>1x10^</td><td rowspan=1 colspan=1>5x10-1</td><td rowspan=1 colspan=1>1x10^1</td><td rowspan=1 colspan=1>1x10^1</td></tr></table>

Simplexa ™ Influenza A H1N1 (2009) Limit of Detection - H1N1   

<table><tr><td rowspan=2 colspan=1>2009 Influenza A Strain</td><td rowspan=1 colspan=2>LoD MagNA Pure extraction(TCIDso/mL)</td><td rowspan=1 colspan=2>LoD QiAgen extraction(TCID5o/mL)</td></tr><tr><td rowspan=1 colspan=1>Swab</td><td rowspan=1 colspan=1>Aspirate</td><td rowspan=1 colspan=1>Swab</td><td rowspan=1 colspan=1>Aspirate</td></tr><tr><td rowspan=1 colspan=1>AVCalifornia/7/2009 NYMC x-179-A</td><td rowspan=1 colspan=1>1.3x101</td><td rowspan=1 colspan=1>2.7x10</td><td rowspan=1 colspan=1>2.7x101</td><td rowspan=1 colspan=1>2.7x101</td></tr><tr><td rowspan=1 colspan=1>A/Swine NY/02/2009 H1N1</td><td rowspan=1 colspan=1>1x101</td><td rowspan=1 colspan=1>1x10^1</td><td rowspan=1 colspan=1>1x10^1</td><td rowspan=1 colspan=1>1x10^1</td></tr></table>

# Analytical Reactivity

<table><tr><td rowspan=1 colspan=1>Influenza A Strain</td><td rowspan=1 colspan=1>Estimated LoD</td></tr><tr><td rowspan=1 colspan=1>APR/8/34 H1N1</td><td rowspan=1 colspan=1>$1x10^}$</td></tr><tr><td rowspan=1 colspan=1>A/New Caledonia/20/99 H1N1</td><td rowspan=1 colspan=1>1x10$</td></tr><tr><td rowspan=1 colspan=1>ATaiwan/42/06 H1N1</td><td rowspan=1 colspan=1>1x10</td></tr><tr><td rowspan=1 colspan=1>AWS/33 H1N1</td><td rowspan=1 colspan=1>$1x10}$</td></tr><tr><td rowspan=1 colspan=1>A/Hong Kong/8/68 H3N2</td><td rowspan=1 colspan=1>$1x10^r}$</td></tr></table>

# Cross-Reactivity

No cross reactivity was detected for either Influenza A or 2009 H1N1 to organisms that are closely related to influenza A or 2009 H1N1, or cause similar clinical symptoms as influenza A or 2009 H1N1, or present as normal flora in the specimen types of interest.

# Interference

Potentially interfering substances were not tested with this methodology; common medications taken by study participants do not appear to inhibit the PCR process.

# Clinical Agreement

S veo , TX (September 2009) and the New South Wales region f Austraia (uly  September 2009).Specmens bln ny u .nl boato r Spe weeti pivr09 nfza  si etcie Le AGRVPFua, validated PCR assay using primer and probe sequences published by the CDC and a well characterized PCR followed by sequencing.Two results were generated or each specien, an influenza A result and a 20 H1 inuza sub-yping result.Both results must be postive to determie that a pecmen s 00 H1inu positive.

prospectively collected nasal/nasoharyngeal swabs nd12nasoharyngeal aspirateswere analyzedushe mpleazaassyhe at e elo atd yoh esul an s Fieen 5) speens 10 swabsn 5 asprats) wee excled om he nalysis beuse there waso were excluded from the 2009 HiN1 Influenza Clinical Agreement Summary tables as sequencing data used to determie subtype was not available.These  speciens ae included in the Influenza A ClinicalAgrent Summary tables.

2009 H1N1 Influenza Clinical Agreement Summary Simplexa™ Influenza A H1N1 (2009) vs. Composite Reference Result - Prospectively Collected Swab   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=5>H1N1 Result - Simplexa™ Influenza A H1N1 (2009)</td></tr><tr><td rowspan=3 colspan=1>FrrEajsodwo</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>H1N1Detected</td><td rowspan=1 colspan=1>H1N1Not Detected</td><td rowspan=1 colspan=1>% Agreement</td></tr><tr><td rowspan=1 colspan=1>H1N1Detected</td><td rowspan=1 colspan=1>101</td><td rowspan=1 colspan=1>101</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>% Positive Agreement100%(101/101)95% CI:96.3-100%</td></tr><tr><td rowspan=1 colspan=1>H1N1Not Detected</td><td rowspan=1 colspan=1>179</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>171</td><td rowspan=1 colspan=1>% Negative Agreement95.5%(171/179)95% CI:91.4-97.7%</td></tr></table>

were excluded because sequencing results to determine sub-types were not available.

2009 H1N1 Influenza Clinical Agreement Summary Simplexa™ Influenza A H1N1 (2009) vs. Composite Reference Result - Prospectively Collected Aspirates   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=5>H1N1 Result - Simplexa ™ Influenza A H1N1 (2009)</td></tr><tr><td rowspan=3 colspan=1>B Fecpsodce</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>H1N1Detected</td><td rowspan=1 colspan=1>H1N1Not Detected</td><td rowspan=1 colspan=1>% Agreement</td></tr><tr><td rowspan=1 colspan=1>H1N1Detected</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>% Positive Agreement100%(24/24)95% CI:86.2-100%</td></tr><tr><td rowspan=1 colspan=1>H1N1Not Detected</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>74</td><td rowspan=1 colspan=1>% Negative Agreement92.5%(74/80)95% CI:84.6-96.5%</td></tr></table>

were excluded because sequencing results to determine sub-types were not available.

Influenza A Clinical Agreement Summary Simplexa™ Influenza A H1N1 (2009) vs. Composite Reference Result - Prospectively Collected Swabs'   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=5>Influenza A Result - Simplexa™ Influenza A H1N1 (2009)</td></tr><tr><td rowspan=3 colspan=1>Fre cosodcte</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Influenza ADetected</td><td rowspan=1 colspan=1>Influenza ANot Detected</td><td rowspan=1 colspan=1>% Agreement</td></tr><tr><td rowspan=1 colspan=1>Influenza ADetected</td><td rowspan=1 colspan=1>116</td><td rowspan=1 colspan=1>116</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>% Positive Agreement100%(116/116)95% CI:96.8-100%</td></tr><tr><td rowspan=1 colspan=1>Influenza ANot Detected</td><td rowspan=1 colspan=1>173</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>% Negative Agreement92.5%(160/173)95% Cl:87.6-95.6%</td></tr></table>

influenza A reference assays.

Influenza A Clinical Agreement Summary Simplexa™ Influenza A H1N1 (2009) vs. Composite Reference Result - Prospectively Colected Aspirates   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=5>Influenza A Result - Simplexa Influenza A H1N1 (2009)</td></tr><tr><td rowspan=3 colspan=1>Rrrg Bcpsodwte</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Influenza ADetected</td><td rowspan=1 colspan=1>Influenza ANot Detected</td><td rowspan=1 colspan=1>% Agreement</td></tr><tr><td rowspan=1 colspan=1>Influenza ADetected</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>% Positive Agreement100%(31/31)95% Cl:89-100%</td></tr><tr><td rowspan=1 colspan=1>Influenza ANot Detected</td><td rowspan=1 colspan=1>76</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>73</td><td rowspan=1 colspan=1>% Negative Agreement96.1%(73/76)95% Cl:89-98.6%</td></tr></table>

a excluded from the analysis because there was no consensus of the influenza A reference assays.

An aditional 14 retrospectively collectednasal/nasopharyngeal swabs and  nasal washes from the Focus Sample westa sre wa ses weecloe alys ecu here as cosus among the reference assay resultsOne1)swab specimen was excluded from he 20091 Infz CncalAgreent ary tables s equncig ata useeterie ubtye was o availabise is included in the Influenza A Clinical Agreement Summary tables.

2009 H1N1 Influenza Clinical Agreement Summary Simplexa ™ Influenza A H1N1 (2009) vs. Composite Reference Result - Retrospectively (   
  

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=6>H1N1 Result - Simplexa™ Influenza A H1N1 (2009)</td></tr><tr><td rowspan=3 colspan=1>Berey reycosodwte</td><td rowspan=1 colspan=1>1.</td><td rowspan=1 colspan=1>.nFA</td><td rowspan=1 colspan=1>H1N1Detected</td><td rowspan=1 colspan=1>H1N1Not Detected</td><td rowspan=1 colspan=1>Indeterminate</td><td rowspan=1 colspan=1>% Agreement</td></tr><tr><td rowspan=1 colspan=1>H1N1Detected</td><td rowspan=1 colspan=1>57</td><td rowspan=1 colspan=1>57</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>% Positive Agreement100%(57/57)95% Cl:93.7-100%</td></tr><tr><td rowspan=1 colspan=1>H1N1Not Detected</td><td rowspan=1 colspan=1>153</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>139</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>% Negative Agreement90.8%(139/153)95% Cl:85.2-94.5%</td></tr></table>

excluded from the analysis because sequencing results there was insufficient sample to perform sequencing.

Tive coll wa we nd  n y e method and by the Simplexa assay.

Influenza A Clinical Agreement Summary Simplexa™ Influenza A H1N1 (2009) vs. Composite Reference Result - Retrospectively Collected Swabs'   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=6>Influenza A Result - Simplexa ™ Influenza A H1N1 (2009):</td></tr><tr><td rowspan=3 colspan=1>Rrry raosodwte</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Influenza ADetected</td><td rowspan=1 colspan=1>Influenza ANot Detected</td><td rowspan=1 colspan=1>Indeterminate</td><td rowspan=1 colspan=1>% Agreement</td></tr><tr><td rowspan=1 colspan=1>Influenza ADetected</td><td rowspan=1 colspan=1>132</td><td rowspan=1 colspan=1>131</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>% Positive Agreement99.2%(131/132)95% Cl:95.8-99.9%</td></tr><tr><td rowspan=1 colspan=1>Influenza ANot Detected</td><td rowspan=1 colspan=1>79</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>66</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>% Negative Agreement83.5%(66/79)95% Cl:73.9-90.1%</td></tr></table>

the influenza A reference assays.

ya n iv and by the Simplexa assay.

Focus Diagnostics, Inc.   
c/o Tara Viviani   
Regulatory Affairs Project Manager 11331 Valley View St.   
Cypress, California 90630

Re: k100148 Trade/Device Name: Simplexa TM Influenza A H1N1 (2009) Regulation Number: 21CFR $\ S 8 6 6 . 3 3 3 2$ EPY Regulation Name: Influenza A H1N1 2009 Real Time RT-PCR Regulatory Class: Class II Product Code: OQW Dated: April 27, 2010 Received: April 29, 2010

Dear Ms. Viviani:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000- 1050. This letter will allow you to begin marketing your device as described in your Section $5 1 0 ( \mathrm { k } )$ premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796- 5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.   
Sally A. Hojvat, M.Sc., Ph.D. Director   
Division of Microbiology Devices   
Office of In Vitro Diagnostic Device Evaluation and Safety   
Center for Devices and Radiological Health

![](images/02bd85c5c92328c107412198aca1f4e27c6394c9ebd48996c3a6ab631b362092.jpg)

# Indications for Use

510(k) Number (if known): K100148

Device Name: Simplexa™M Influenza A H1N1 (2009)

Indications for Use:

The Focus Diagnostics Simplexa™M Influenza A H1N1 (2009) assay is intended for use on the 3M Integrated Cycler as part of the Microfluidic Molecular System for the in vitro qualitative detection and differentiation of influenza A and 2009 H1N1 influenza viral RNA in nasopharyngeal swabs (NPS), nasal swabs (NS), and nasopharyngeal aspirates (NPA) from human patients with signs and symptoms of respiratory infection in conjunction with clinical and epidemiological risk factors.

Negative results do not preclude influenza virus infection and should not be used as the sole basis for treatment or other patient management decisions.

Performance characteristics for influenza A were established during the 2009-2010 influenza season when 2009 H1N1 influenza was the predominant influenza A virus in circulation. When other Influenza A viruses are emerging, performance characteristics may vary.

If infection with a novel Influenza A virus is suspected based on current clinical and epidemiological screening criteria recommended by public health authorities, specimens should be collected with appropriate infection control precautions for novel virulent Influenza viruses and sent to state or local health department for testing. Viral culture should not be attempted in these cases unless a BSL $^ { 3 + }$ facility is available to receive and culture specimens.

Prescription Use X (Part 21 CFR 801 Subpart D)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostics (OIVD)

![](images/e911755ba0fc7bf85a6acdae23ea2ce1f2b155c35f4d8eb433770f9082c0e943.jpg)

Office of In Vitro Diagnostic Device Evaluation and Safety